Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Classical hematology 9Gynecologic 5Breast 4Genitourinary 1

Conditions

Ovarian Neoplasms 92Fallopian Tube Neoplasms 25Breast Neoplasms 21Endometrial Neoplasms 19Carcinoma, Ovarian Epithelial 12Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Neoplasms 6Fanconi Anemia, Complementation Group D1 5Uterine Cervical Neoplasms 4Recurrence 4Neoplasm Metastasis 4Carcinoma, Renal Cell 3Uterine Neoplasms 2Stomach Neoplasms 2Peritoneal Neoplasms 2Ovarian Diseases 2Carcinosarcoma 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Relapsed Ovarian Cancers Patients 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Prostatic Neoplasms, Castration-Resistant 1Platinum-sensitive Ovarian Cancer 1Platinum-Refractory Fallopian Tube Carcinoma 1

Interventions

olaparib 5talazoparib 1liposomal doxorubicin 1Trabectedin 1Surveys and Questionnaires 1Genetic Counseling 1Demography 1Data Collection 1Counseling 1Cognitive Behavioral Therapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Fanconi Anemia, Complementation Group D1 × olaparib × Gynecologic × Clear all
NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

AstraZeneca

Phase 2 Completed
265 enrolled 25 charts 1 FDA
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

AstraZeneca

Phase 1 Completed
98 enrolled
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

AstraZeneca

Phase 2 Completed
97 enrolled 22 charts
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02418624 2019-01-16

REVIVAL

The Netherlands Cancer Institute

Phase 1 Completed
25 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

NCT00494442 2018-08-01

ICEBERG 2

AstraZeneca

Phase 2 Completed
58 enrolled 13 charts
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡